Team:Washington/Gram Negative/Build

From 2010.igem.org

(Difference between revisions)
(Header 1)
(Engineering the Toxin Antitoxin HSL-inducible circuit)
 
(87 intermediate revisions not shown)
Line 26: Line 26:
<!---------------------------------------PAGE CONTENT GOES BELOW THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES BELOW THIS---------------------------------------->
-
=Header 1=
 
-
==Why induce tse2 expression only when a gram-negative pathogen is present?==
+
=Recombineering the Promoter Region of the Type VI Secretion System=
-
A type six secretion system +/Tse2 +/Tsi2+ strain of ''E. coli'' could be administered like a traditional antibiotic after a pathogen infection by having a strain that constitutively expresses Tse2 and Tsi2. However, this would be a fairly brute force method of anti-bacterial comparable to traditional chemical antibiotics in its damage to the gut’s natural flora, and is only advantage over chemical antibiotics would be the current lack of Tse2 resistant pathogenic bacterial strains. If T se2 expression is induced by a chemical signal indicative of the presence of a pathogen, any unintended disruption of the natural gut flora will be limited to the area infected with pathogens, and the risk of Tse2 resistance would decrease. In addition, if Tse2 is only expressed when pathogenic bacteria are present, a Tse2+/ Tsi2+/ T6SS strain could be used in order to help prevent pathogenic gut infections, and could be a permanent member of the gut flora. Such a preventative strain could even be used against multiple gut pathogens by merely including multiple copies of tse2, each of which would respond to signals indicative of different pathogens.  
+
[[Image:Washington_Recombineering_basic.png|750px|center|thumb|Schematic Showing the Engineering of the Fosmid to Contain a Divergent T7 Promoter Instead of the Native ''Pseudomonas'' Promoter]]
-
==3OC6HSL as a proxy for a pathogenic signal==
+
Our goal was to replace the native ''P. aeruginosa'' regulation of the Type VI Secretion System with one that can be utilized by the ''E. coli'' transcriptional machineryIn order to replace the native promoters with more robust T7 promoters we used a technique called [https://2010.igem.org/Team:Washington/Protocols/Recombineering Recombineering] to flip out the region containing both promoters and replace it with a gene cassette as follows. We designed primers to create a cassette using PCR, containing the ''galK'' galactose metabolism gene flanked by 50 base pairs of homology just outside of the promoter region in the fosmid. The cassette was inserted, giving us a selection factor for our final insertion of our new promotersA new promoter cassette was designed in total using oligos that encoded the two T7 promoters flanked by the same 50 base pairs of homology used previously, and inserted using recombineering into the fosmid that contained ''galK'' in the promoter region.
-
3OC6HSL is a small organic molecule produced by "Vibrio fischeri" as a quorum sensing signal( include structural image) . Quorum sensing is a pathway where every bacterial cell produces and excretes a specific signalling molecule. When a specific density of bacteria is present in a region ( a quorum), the level of quorum sensing molecules is sufficient to induce or repress specific genes in order to tune gene expression to an environment of high cellular density. In "V. fischeri", 3OC6HSL permeates the cellular membrane and binds to the transcriptional factor LuxR, changing the conformation of LuxR in such a way that LuxR can bind to a DNA sequence within the Lux promoter, activating downstream transcription. While the 3OC6HSl-LuxR quorum sensing system is not present in any human pathogens, placing Tse2 downstream from a Lux promoter in a strain expressing LuxR does provide a good proof of concept showing that Tse2 can be regulated in such a way that Tse2 expression occurs only in the presence of a target bacterial pathogen. Many pathogenic bacteria do engage in quorum sensing. This system could be easily converted to express Tse2 only in the presence of a specific pathogenic species by changing the promoter and transcriptional factor. A major advantange of using the luxR quorum sensing system is that a well charactarized part containing both the LuxR transcriptional factor and Lux promoter already exists in the registry([http://partsregistry.org/Part:BBa_F2620 F2620]). This allowed for amplification from genomic DNA to be skipped, saving time.    
+
 
 +
=Engineering the Toxin Antitoxin HSL-inducible circuit=
 +
[[Image:Washington_Building_Tse2_circuit.png|center|750px|thumb|Schematic Detailing the Transfer of Tse2 and Tsi2 from ''P. Aeruginosa'' into pSB3k3]]
 +
The Tse2/Tsi2 locus was amplified from ''P. aeruginosa'' genomic DNA using PCR.  Primers were used that amplified the region from the start codon of Tse2 to the stop codon of Tsi2.  The Tse2 and Tsi2 locus was then placed downstream from F2620 via [[Team:Washington/Tools_Used/Next-Gen_Cloning|Gibson Cloning]]. Gibson cloning is a method that joins regions of homology found on the 5' and 3' ends of linearized molecules. The end result of this Gibson cloning reaction is a circularized plasmid containing the final F2620.Tse2.Tsi2 construct in pSB3K3. The circularized plasmid is then transformed into electrocompetent ''E. coli'' Dh5a and the resulting colonies were screened for the insert of expected length via double restriction digest followed by agarose gel electrophoresis. The plasmids that showed inserts of expected length were sequenced, and it was determined that multiple plasmids had correct F2620.Tse2.Tsi2 inserts.
 +
 
 +
 
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS---------------------------------------->
<div style="text-align:center">
<div style="text-align:center">
-
'''&larr; [[Team:Washington/Project/Mougous/Design|Designing the Gram(-) Therapeutic]]'''
+
'''&larr; [[Team:Washington/Gram Negative/Design|Designing the Gram(-) Therapeutic]]'''
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
&nbsp;
-
'''[[Team:Washington/Project/Mougous/Test|Testing the Gram(-) Therapeutic]] &rarr;'''
+
'''[[Team:Washington/Gram Negative/Test|Testing the Gram(-) Therapeutic]] &rarr;'''
</div>
</div>
{{Template:Team:Washington/Templates/Footer}}
{{Template:Team:Washington/Templates/Footer}}

Latest revision as of 16:49, 26 October 2010


Recombineering the Promoter Region of the Type VI Secretion System

Schematic Showing the Engineering of the Fosmid to Contain a Divergent T7 Promoter Instead of the Native Pseudomonas Promoter

Our goal was to replace the native P. aeruginosa regulation of the Type VI Secretion System with one that can be utilized by the E. coli transcriptional machinery. In order to replace the native promoters with more robust T7 promoters we used a technique called Recombineering to flip out the region containing both promoters and replace it with a gene cassette as follows. We designed primers to create a cassette using PCR, containing the galK galactose metabolism gene flanked by 50 base pairs of homology just outside of the promoter region in the fosmid. The cassette was inserted, giving us a selection factor for our final insertion of our new promoters. A new promoter cassette was designed in total using oligos that encoded the two T7 promoters flanked by the same 50 base pairs of homology used previously, and inserted using recombineering into the fosmid that contained galK in the promoter region.

Engineering the Toxin Antitoxin HSL-inducible circuit

Schematic Detailing the Transfer of Tse2 and Tsi2 from P. Aeruginosa into pSB3k3

The Tse2/Tsi2 locus was amplified from P. aeruginosa genomic DNA using PCR. Primers were used that amplified the region from the start codon of Tse2 to the stop codon of Tsi2. The Tse2 and Tsi2 locus was then placed downstream from F2620 via Gibson Cloning. Gibson cloning is a method that joins regions of homology found on the 5' and 3' ends of linearized molecules. The end result of this Gibson cloning reaction is a circularized plasmid containing the final F2620.Tse2.Tsi2 construct in pSB3K3. The circularized plasmid is then transformed into electrocompetent E. coli Dh5a and the resulting colonies were screened for the insert of expected length via double restriction digest followed by agarose gel electrophoresis. The plasmids that showed inserts of expected length were sequenced, and it was determined that multiple plasmids had correct F2620.Tse2.Tsi2 inserts.


Designing the Gram(-) Therapeutic       Testing the Gram(-) Therapeutic